GLP-1 receptor agonist weight-loss drugs such as semaglutide may protect the cardiovascular system independent of weight loss.
“An analysis of the SELECT trial explored this question in adults with cardiovascular disease and overweight or obesity, but without diabetes. The study followed 17,604 participants aged 45 years or older across 41 countries for an average of more than three years.”